Kitano Hiroyuki, Ohge Hiroki, Tadera Kayoko, Kohada Yuki, Hatayama Tomoya, Shikuma Hiroyuki, Tasaka Ryo, Takemoto Kenshiro, Miyamoto Shunsuke, Kobatake Kohei, Sekino Yohei, Kitagawa Hiroki, Kashiyama Seiya, Hinata Nobuyuki
Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8551, Japan.
Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, 734-8551, Japan.
World J Urol. 2025 Sep 15;43(1):554. doi: 10.1007/s00345-025-05936-3.
To identify bacteria potentially involved in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) classified as nonbacterial and evaluate the clinical effectiveness of antibiotic therapy against these pathogens.
Patients were classified into two groups-CP/CPPS category IIIb and the bacterial prostatitis subgroup of CP/CPPS-based on the presence or absence of pyuria and bacteriuria in urine samples obtained before and after prostatic massage. Treatment efficacy was compared between the two groups. The bacterial prostatitis subgroup was further stratified according to whether uropathogens or non-uropathogens were detected, and treatment responses were analyzed accordingly.
A total of 28 patients were classified in the CP/CPPS category IIIb and 17 patients in the bacterial prostatitis subgroup. The bacterial prostatitis subgroup showed a significantly greater reduction in National Institutes of Health-Chronic Prostatitis Symptom Index total scores compared with the IIIb group, particularly in the pain domain, which also showed significant improvement over time. The quality-of-life scores also improved in this subgroup. Within the bacterial prostatitis subgroup, both uropathogen-positive and non-uropathogen-positive patients showed a reduction in pain scores, with significantly greater improvement observed in the non-uropathogen group.
These findings suggest that some patients classified as CP/CPPS category IIIb under conventional diagnostic methods may, in fact, have bacterial involvement. Antibiotic therapy may be effective in such cases, including those with non-uropathogenic bacterial detection.
识别可能与分类为非细菌性的慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)相关的细菌,并评估针对这些病原体的抗生素治疗的临床效果。
根据前列腺按摩前后尿液样本中是否存在脓尿和菌尿,将患者分为两组——CP/CPPS IIIb类和CP/CPPS的细菌性前列腺炎亚组。比较两组之间的治疗效果。细菌性前列腺炎亚组根据是否检测到尿路病原体或非尿路病原体进一步分层,并相应分析治疗反应。
共有28例患者被分类为CP/CPPS IIIb类,17例患者被分类为细菌性前列腺炎亚组。与IIIb组相比,细菌性前列腺炎亚组的美国国立卫生研究院慢性前列腺炎症状指数总分显著降低,尤其是在疼痛领域,随着时间的推移也有显著改善。该亚组的生活质量评分也有所提高。在细菌性前列腺炎亚组中,尿路病原体阳性和非尿路病原体阳性患者的疼痛评分均降低,非尿路病原体组的改善更为显著。
这些发现表明,一些在传统诊断方法下被分类为CP/CPPS IIIb类的患者实际上可能有细菌感染。抗生素治疗在这些情况下可能有效,包括那些检测到非尿路致病性细菌的患者。